Spruce Biosciences, Inc. (SPRB)

US — Healthcare Sector
Peers: ABOS  GRTX  INZY  ELDN  STTK  FHTX  TSHA 

Automate Your Wheel Strategy on SPRB

With Tiblio's Option Bot, you can configure your own wheel strategy including SPRB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SPRB
  • Rev/Share 0.0662
  • Book/Share 0.3487
  • PB 0.3183
  • Debt/Equity 0.1308
  • CurrentRatio 1.9517
  • ROIC -3.3478

 

  • MktCap 4687674.0
  • FreeCF/Share -1.2227
  • PFCF -0.0872
  • PE -0.088
  • Debt/Assets 0.0633
  • DivYield 0
  • ROE -1.4315

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade SPRB JMP Securities Mkt Outperform Market Perform -- -- Dec. 11, 2024
Downgrade SPRB Oppenheimer Outperform Perform -- -- Dec. 11, 2024

News

HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder
SPRB
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder Topline Results Anticipated in the First Half of 2026 MUNICH, Germany and SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that the first patient has been dosed in the Phase 2 clinical trial called “Tildacerfont as Antidepressant Medication and Relief in Depression” (TAMARIND).

Read More
image for news HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder

About Spruce Biosciences, Inc. (SPRB)

  • IPO Date 2020-10-09
  • Website https://www.sprucebiosciences.com
  • Industry Biotechnology
  • CEO Javier Szwarcberg
  • Employees 20
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.